| Date | Time | Source | Headline | Symbol | Company |
| 04/29/2024 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024 | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 04/03/2024 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 03/26/2024 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid” | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 03/07/2024 | 4:01PM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 03/07/2024 | 8:06AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 03/07/2024 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 02/29/2024 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024 | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 02/13/2024 | 8:05AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 02/13/2024 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 01/31/2024 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 01/22/2024 | 8:21PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 12/15/2023 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 12/14/2023 | 8:05AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 12/14/2023 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 12/06/2023 | 8:05AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 12/06/2023 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/28/2023 | 8:06AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/28/2023 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/20/2023 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/09/2023 | 4:02PM | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/09/2023 | 8:05AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/09/2023 | 8:05AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/09/2023 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/08/2023 | 7:56PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/03/2023 | 4:54PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/01/2023 | 5:50PM | Dow Jones News | Phathom Pharmaceuticals Gets FDA Approval for Voquezna Treatment | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/01/2023 | 5:06PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 11/01/2023 | 5:00PM | GlobeNewswire Inc. | Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 10/30/2023 | 8:05AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |
| 10/30/2023 | 8:00AM | GlobeNewswire Inc. | Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults | NASDAQ:PHAT | Phathom Pharmaceuticals Inc |